ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BFRG Bullfrog AI Holdings Inc

2.87
0.00 (0.00%)
Pre Market
Last Updated: 04:00:08
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 2.72
Ask Price 3.50
News -
Day High

Low
2.36

52 Week Range

High
8.35

Day Low
Company Name Stock Ticker Symbol Market Type
Bullfrog AI Holdings Inc BFRG NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 2.87 04:00:08
Open Price Low Price High Price Close Price Prev Close
2.87
Trades Volume Avg Volume 52 Week Range
0 0 - 2.36 - 8.35
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.87 USD

Bullfrog AI Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
17.49M 6.09M - 65k -5.36M -0.88 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Bullfrog AI News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BFRG Message Board. Create One! See More Posts on BFRG Message Board See More Message Board Posts

Historical BFRG Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.933.02992.692.8363,860-0.06-2.05%
1 Month3.443.442.693.0584,267-0.57-16.57%
3 Months3.835.522.694.22285,736-0.96-25.07%
6 Months2.958.352.364.551,352,844-0.08-2.71%
1 Year5.438.352.364.531,185,167-2.56-47.15%
3 Years5.309.502.364.851,383,100-2.43-45.85%
5 Years5.309.502.364.851,383,100-2.43-45.85%

Bullfrog AI Description

Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company. The Company is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. The Company¿s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. The Company¿s therapeutic pipeline includes siRNA and Mebendazole. Its siRNA targets Beta2-spectrin in the treatment of human diseases such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

Your Recent History

Delayed Upgrade Clock